These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Elevated expression of nuclear receptor-binding SET domain 3 promotes pancreatic cancer cell growth. Sun Y; Xie J; Cai S; Wang Q; Feng Z; Li Y; Lu JJ; Chen W; Ye Z Cell Death Dis; 2021 Oct; 12(10):913. PubMed ID: 34615858 [TBL] [Abstract][Full Text] [Related]
3. NSD3-Induced Methylation of H3K36 Activates NOTCH Signaling to Drive Breast Tumor Initiation and Metastatic Progression. Jeong GY; Park MK; Choi HJ; An HW; Park YU; Choi HJ; Park J; Kim HY; Son T; Lee H; Min KW; Oh YH; Lee JY; Kong G Cancer Res; 2021 Jan; 81(1):77-90. PubMed ID: 32967925 [TBL] [Abstract][Full Text] [Related]
4. Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases. Li W; Tian W; Yuan G; Deng P; Sengupta D; Cheng Z; Cao Y; Ren J; Qin Y; Zhou Y; Jia Y; Gozani O; Patel DJ; Wang Z Nature; 2021 Feb; 590(7846):498-503. PubMed ID: 33361816 [TBL] [Abstract][Full Text] [Related]
5. Dissecting the Immunological Profiles in Xu D; Liu S; Wu X; Marti TM; Dorn P; Schmid RA; Peng RW; Shu Y Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291782 [TBL] [Abstract][Full Text] [Related]
6. In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L. Morishita M; Mevius D; di Luccio E BMC Struct Biol; 2014 Dec; 14():25. PubMed ID: 25494638 [TBL] [Abstract][Full Text] [Related]
7. Systematic perturbations of SETD2, NSD1, NSD2, NSD3, and ASH1L reveal their distinct contributions to H3K36 methylation. Shipman GA; Padilla R; Horth C; Hu B; Bareke E; Vitorino FN; Gongora JM; Garcia BA; Lu C; Majewski J Genome Biol; 2024 Oct; 25(1):263. PubMed ID: 39390582 [TBL] [Abstract][Full Text] [Related]
8. [NSD3 suppresses LPS-triggered TNF-α production via promoting the dimethylation of histone H3K36 in macrophages]. Liu Z; Cheng Q; Yang L; Sun Y Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2018 Jun; 34(6):481-487. PubMed ID: 30236198 [TBL] [Abstract][Full Text] [Related]
9. Development of mammary hyperplasia, dysplasia, and invasive ductal carcinoma in transgenic mice expressing the 8p11 amplicon oncogene NSD3. Turner-Ivey B; Smith EL; Rutkovsky AC; Spruill LS; Mills JN; Ethier SP Breast Cancer Res Treat; 2017 Jul; 164(2):349-358. PubMed ID: 28484924 [TBL] [Abstract][Full Text] [Related]
10. The methyltransferase NSD3 has chromatin-binding motifs, PHD5-C5HCH, that are distinct from other NSD (nuclear receptor SET domain) family members in their histone H3 recognition. He C; Li F; Zhang J; Wu J; Shi Y J Biol Chem; 2013 Feb; 288(7):4692-703. PubMed ID: 23269674 [TBL] [Abstract][Full Text] [Related]
11. PPAPDC1B and WHSC1L1 are common drivers of the 8p11-12 amplicon, not only in breast tumors but also in pancreatic adenocarcinomas and lung tumors. Mahmood SF; Gruel N; Nicolle R; Chapeaublanc E; Delattre O; Radvanyi F; Bernard-Pierrot I Am J Pathol; 2013 Nov; 183(5):1634-1644. PubMed ID: 24051013 [TBL] [Abstract][Full Text] [Related]
12. KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition. Pan Y; Han H; Hu H; Wang H; Song Y; Hao Y; Tong X; Patel AS; Misirlioglu S; Tang S; Huang HY; Geng K; Chen T; Karatza A; Sherman F; Labbe KE; Yang F; Chafitz A; Peng C; Guo C; Moreira AL; Velcheti V; Lau SCM; Sui P; Chen H; Diehl JA; Rustgi AK; Bass AJ; Poirier JT; Zhang X; Ji H; Zhang H; Wong KK Cancer Cell; 2023 Jan; 41(1):88-105.e8. PubMed ID: 36525973 [TBL] [Abstract][Full Text] [Related]
13. Targeting H3K36 methyltransferases NSDs: a promising strategy for tumor targeted therapy. Peng X; Peng Q; Zhong L Signal Transduct Target Ther; 2021 Jun; 6(1):220. PubMed ID: 34083510 [No Abstract] [Full Text] [Related]
14. Protective effect of histone methyltransferase NSD3 on ISO-induced cardiac hypertrophy. Chen K; Jian D; Zhao L; Zang X; Song W; Ma J; Jia Z; Wang X; Gao C FEBS Lett; 2019 Sep; 593(18):2556-2565. PubMed ID: 31254363 [TBL] [Abstract][Full Text] [Related]
15. NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism. French CA; Rahman S; Walsh EM; Kühnle S; Grayson AR; Lemieux ME; Grunfeld N; Rubin BP; Antonescu CR; Zhang S; Venkatramani R; Dal Cin P; Howley PM Cancer Discov; 2014 Aug; 4(8):928-41. PubMed ID: 24875858 [TBL] [Abstract][Full Text] [Related]
17. BCL11A interacts with SOX2 to control the expression of epigenetic regulators in lung squamous carcinoma. Lazarus KA; Hadi F; Zambon E; Bach K; Santolla MF; Watson JK; Correia LL; Das M; Ugur R; Pensa S; Becker L; Campos LS; Ladds G; Liu P; Evan GI; McCaughan FM; Le Quesne J; Lee JH; Calado D; Khaled WT Nat Commun; 2018 Aug; 9(1):3327. PubMed ID: 30127402 [TBL] [Abstract][Full Text] [Related]
18. Silencing of histone methyltransferase NSD3 reduces cell viability in osteosarcoma with induction of apoptosis. Liu Z; Piao L; Zhuang M; Qiu X; Xu X; Zhang D; Liu M; Ren D Oncol Rep; 2017 Nov; 38(5):2796-2802. PubMed ID: 28901481 [TBL] [Abstract][Full Text] [Related]
19. WHSC1L1 drives cell cycle progression through transcriptional regulation of CDC6 and CDK2 in squamous cell carcinoma of the head and neck. Saloura V; Vougiouklakis T; Zewde M; Kiyotani K; Park JH; Gao G; Karrison T; Lingen M; Nakamura Y; Hamamoto R Oncotarget; 2016 Jul; 7(27):42527-42538. PubMed ID: 27285764 [TBL] [Abstract][Full Text] [Related]
20. Histones Methyltransferase NSD3 Inhibits Lung Adenocarcinoma Glycolysis Through Interacting with PPP1CB to Decrease STAT3 Signaling Pathway. Zhou Y; Peng X; Fang C; Peng X; Tang J; Wang Z; Long Y; Chen J; Peng Y; Zhang Z; Zhou Y; Tang J; Liao J; Xiao D; Tao Y; Shi Y; Liu S Adv Sci (Weinh); 2024 Oct; 11(38):e2400381. PubMed ID: 39119928 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]